USFDA Regulatory Strategy & Device Assessment

The temptation with the US market is to jump straight to the submission, because that feels like progress. It is usually a mistake. The FDA’s routes differ so dramatically in evidence, cost and time that committing to execution before confirming the route is like setting off on a journey before deciding the destination. A device wrongly assumed to be a straightforward 510(k) that turns out to need a De Novo, or clinical evidence, can have months and a great deal of money sunk into the wrong preparation before the error is caught.

A regulatory strategy front-loads the thinking so the execution is aimed correctly. It answers the questions that determine everything downstream — what class, what route, what evidence, what sequence, how long — before the expensive work begins. We treat the strategy as the highest-leverage part of the whole US effort, because a sound one makes the submission that follows efficient, while a missing one turns it into a series of costly corrections.

• FDA routes differ hugely in evidence, cost and time.
• Executing before confirming the route wastes months and money.
• Strategy aims the whole effort correctly from the start.

Everything begins with how the FDA classifies your device. Class I is low risk, Class II moderate, Class III high, and that class largely sets the route — from exempt, through 510(k) and De Novo, to PMA. Alongside the class sits the product code, the FDA’s specific categorisation that ties your device to a regulation and to the expectations for that device type. Establishing the classification and product code correctly is the foundational act of US strategy, and for a novel or borderline device it requires genuine analysis rather than a quick lookup.

We determine the classification and product code by analysing the device’s intended use and technology against the FDA’s classification framework and its database of existing devices. Where a device is genuinely new or sits on a boundary, this is a matter of reasoned judgement, and getting it right is what prevents the whole strategy from being built on a mistaken premise. It is the keystone, and we treat it accordingly.

With the classification established, the pathway usually follows — but the choice deserves scrutiny because the routes are so different. Many Class I and some Class II devices are exempt from premarket submission entirely, needing only registration and listing. Most Class II devices go through the 510(k), demonstrating substantial equivalence to a legally marketed predicate. A genuinely novel low-to-moderate risk device with no predicate may use the De Novo route to create a new classification. High-risk Class III devices require a PMA, with its clinical-evidence burden. Each carries a different investment.

We assess which route your device genuinely belongs on, including the cases where there is a real choice or a strategic decision to be made — whether a device might be positioned for a 510(k) versus a De Novo, for instance. Getting this right means you neither over-prepare for a lighter route nor walk into a heavier one unready, and it sets a realistic expectation of the time and cost ahead, which is often the most valuable output of the whole assessment.

For the common 510(k) route, the strategy lives or dies on the predicate and the evidence. A predicate is a legally marketed device you compare yours to in order to establish substantial equivalence, and choosing a strong, defensible one is the single most important factor in a smooth 510(k). Alongside it, you have to map the performance testing — bench, biocompatibility, and sometimes clinical — that the comparison and the device type demand. A weak predicate or a testing gap is the classic cause of an FDA hold that adds months.

We run the predicate search and the evidence assessment as part of the strategy, so you go into execution knowing which predicate you will rely on and exactly what testing stands between you and the submission. This honest gap analysis — what you have versus what the route requires — is where the real work of strategy happens. Discovering a missing study at the strategy stage is a planning item; discovering it mid-submission is a crisis, and the assessment is designed to make sure it is the former.

• A defensible predicate is the key to a smooth 510(k).
• Bench, biocompatibility and sometimes clinical testing must be mapped.
• Gaps found at strategy stage are cheap; found mid-submission, costly.

A strategy is not just which route but in what order. Testing, quality-system readiness and the submission itself have dependencies, and sequencing them well avoids both idle waiting and wasted rework — you do not want to complete testing only to find the design changed, or to build a submission before the supporting studies are done. A well-sequenced plan also sets realistic timing, so the business can plan a launch around a credible date rather than an optimistic guess.

We build the sequence and the timeline into the strategy, so the US programme unfolds in a logical order with realistic milestones. This matters commercially as much as regulatorily: a device team that knows when clearance is genuinely achievable can plan manufacturing, marketing and funding around it, whereas one working to a fantasy timeline sets itself up for repeated disappointment. Honest sequencing and timing are part of what makes a strategy trustworthy rather than merely hopeful.

Few device companies target only the United States, and the smart strategy accounts for that from the start. Much of the evidence a US route demands — the testing, the risk management, the quality system — is the same evidence other markets want, if it is generated with reuse in mind. A strategy that treats the US in isolation can produce single-purpose evidence and force the whole exercise to be repeated for Europe or India; one that plans across markets builds an evidence base that serves them collectively.

We align the US strategy with your broader market ambitions, so the work done for the FDA also supports your CE marking, your CDSCO registration and wherever else you are heading. This cross-market view is one of the clearest ways a good regulatory strategy pays for itself: the same rigour that gets you into the US efficiently also lowers the cost of every market that follows, turning a series of separate climbs into one coordinated ascent.